Immunex regulatory update

The new filing is in addition to a pending product license amendment IMNX filed in 1993 for the use of Leukine to accelerate white cell recovery following chemotherapy to treat a broad range of malignancies. IMNX said it chose to file a separate PLA because the data was significant enough to stand on its own. ...